Rezurock (belumosudil) — CareFirst (Caremark)
Chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy
Initial criteria
- Member has failed two or more lines of systemic therapy
- Member age ≥ 12 years
Reauthorization criteria
- Member does not have evidence of unacceptable toxicity while on the current regimen
- Member has not experienced clinically significant progression of cGVHD (i.e., progression that requires new systemic therapy) while on the current regimen
Approval duration
12 months